The molecular logic of pemphigus and impetigo: The desmoglein story

Veterinary Dermatology

Volumn 20, Issue 5-6, 2009, Pages 308-312

  Amagai, Masayuki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOGLEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMPETIGO; METABOLISM; PATHOPHYSIOLOGY; PEMPHIGUS; PHYSIOLOGY; STAPHYLOCOCCAL SCALDED SKIN SYNDROME;

ANIMALS; DESMOGLEINS; GENE EXPRESSION REGULATION; HUMANS; IMPETIGO; PEMPHIGUS; STAPHYLOCOCCAL SCALDED SKIN SYNDROME;

STAPHYLOCOCCUS AUREUS;

EID: 73149118465     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2009.00831.x     Document Type: Article

References (26)

1. Beutner EH, Jordon RE. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proceedings of the Society of Experimental Biology and Medicine 1964 117 : 505 510.
2. Schiltz JR, Michel B. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. Journal of Investigative Dermatology 1976 67 : 254 260.
3. Anhalt GJ, Labib RS, Voorhees JJ et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. New England Journal of Medicine 1982 306 : 1189 1196.
4. Stanley JR, Yaar M, Hawley NP et al. Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. Journal of Clinical Investigation 1982 70 : 281 288.
5. Hashimoto T, Ogawa MM, Konohana A et al. Detection of pemphigus vulgaris and pemphigus foliaceus antigens by immunoblot analysis using different antigen sources. Journal of Investigative Dermatology 1990 94 : 327 331. (Pubitemid 20061641)
6. Koch PJ, Walsh MJ, Schmelz M et al. Identification of desmoglein, a constitutive desmosomal glycoprotein, as a member of the cadherin family of cell adhesion molecules. European Journal of Cell Biology 1990 53 : 1 12.
7. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991 67 : 869 877.
8. Sams WMJ, Jordon RE. Correlation of pemphigoid and pemphigus antibody titres with activity of disease. British Journal of Dermatology 1971 84 : 7 13.
9. Cheng SW, Kobayashi M, Tanikawa A et al. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmoglein 1 and 3. British Journal of Dermatology 2002 147 : 261 265.
10. Amagai M, Karpati S, Prussick R et al. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. Journal of Clinical Investigation 1992 90 : 919 926.
11. Amagai M, Hashimoto T, Shimizu N et al. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. Journal of Clinical Investigation 1994 94 : 59 67.
12. Amagai M, Hashimoto T, Green KJ et al. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. Journal of Investigative Dermatology 1995 104 : 895 901.
13. Tsunoda K, Ota T, Aoki M et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. Journal of Immunology 2003 170 : 2170 2178.
14. Payne AS, Ishii K, Kacir S et al. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. Journal of Clinical Investigation 2005 115 : 888 899.
15. Mahoney MG, Wang Z, Rothenberger KL et al. Explanation for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. Journal of Clinical Investigation 1999 103 : 461 468.
16. Amagai M, Tsunoda K, Zillikens D et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. Journal of the American Academy of Dermatology 1999 40 : 167 170.
17. Wu H, Wang ZH, Yan A et al. Protection against pemphigus foliaceus by desmoglein 3 in neonates. New England Journal of Medicine 2000 343 : 31 5.
18. Melish ME, Glasgow LA. The staphylococcal scalded skin syndrome: development of an experimental model. New England Journal of Medicine 1970 282 : 1114 1119.
19. Amagai M, Matsuyoshi N, Wang ZH et al. Toxin in bullous impetigo and staphylococcal scalded skin syndrome targets desmoglein 1. Nature Medicine 2000 6 : 1275 1277.
20. Amagai M, Yamaguchi T, Hanakawa Y et al. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. Journal of Investigative Dermatology 2002 118 : 845 850.
21. Yamaguchi T, Nishifuji K, Sasaki M et al. Identification of Staphylococcus aureus etd pathogenicity island which encodes a novel exfoliative toxin, ETD, and EDIN-B. Infection and Immunity 2002 70 : 5835 5845.
22. Vath GM, Earhart CA, Rago JV et al. The structure of the superantigen exfoliative toxin A suggests a novel regulation as a serine protease. Biochemistry 1997 36 : 1559 1566.
23. Cavarelli J, Prevost G, Bourguet W et al. The structure of Staphylococcus aureus epidermolytic toxin A, an atypic serine protease, at 1.7 Å resolution. Structure 1997 5 : 813 824.
24. Vath GM, Earhart CA, Monie DD et al. The crystal structure of exfoliative toxin B: a superantigen with enzymatic activity. Biochemistry 1999 38 : 10239 10246.
25. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. New England Journal of Medicine 2006 355 : 1800 1810.
26. Anzai H, Stanley JR, Amagai M. Production of low titers of anti-desmoglein 1 IgG autoantibodies in some patients with staphylococcal scalded skin syndrome. Journal of Investigative Dermatology 2006 126 : 2139 2141.